GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
Completed
- Conditions
- Dwarfism, PituitaryTurner Syndrome
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00097526
A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)
Completed
- Conditions
- End-Stage Renal DiseaseChronic Renal Insufficiency
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 395
- Registration Number
- NCT00097617
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1953
- Registration Number
- NCT00097578
- Locations
- 🇺🇸
Genentech Central Contact, South San Francisco, California, United States
A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone
Completed
- Conditions
- Turner Syndrome
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1696
- Registration Number
- NCT00097552
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
Completed
- Conditions
- Lymphoma, Non Hodgkin
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 2740
- Registration Number
- NCT00097565
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
Completed
- Conditions
- Dwarfism, Pituitary
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00097513
- Locations
- 🇺🇸
Genentech Central Contact, South San Francisco, California, United States
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
Completed
- Conditions
- MetastasesBreast Cancer
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT00097487
An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)
Completed
- Conditions
- PsoriasisPregnancy
- First Posted Date
- 2004-11-22
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00097240
- Locations
- 🇺🇸
FOLLOW Raptiva Pregnancy Registry, Morrisville, North Carolina, United States
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
Phase 2
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2004-11-19
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00097188
- Locations
- 🇺🇸
Michigan Institute For Neurological Disorders, Farmington Hills, Michigan, United States
🇺🇸Neurology and Neuroscience Assoc.,INC, Akron, Ohio, United States
🇺🇸MS Center of Vero Beach, Vero Beach, Florida, United States
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Phase 3
Completed
- Conditions
- Breast CancerColorectal CancerMetastases
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00096967
© Copyright 2025. All Rights Reserved by MedPath